The Online Investor
Ionis Pharmaceuticals Inc (IONS)

Ionis Pharmaceuticals is engaged in discovering and developing RNA-targeted therapeutics. Co.'s commercial medicines are: SPINRAZA, a survival motor neuron-2, directed antisense medicine for the treatment of spinal muscular atrophy in pediatric and adult patients; TEGSEDI, an RNA-targeted medicine designed to reduce the production of TTR protein; and WAYLIVRA, an antisense medicine designed to treat people with rare, hereditary diseases. Co. has drugs in pivotal studies: tominersen for Huntington's disease, tofersen for SOD1-ALS, AKCEA-APO(a)-LRx for cardiovascular disease, and AKCEA-TTR-LRx for various forms of TTR amyloidosis.

IONS SEC Filing Email Alerts Service
Company Name: 
Ionis Pharmaceuticals Inc
Drugs & Pharmaceuticals
Number of ETFs Holding IONS: 
Total Market Value Held by ETFs: 
Total Market Capitalization: 
% of Market Cap. Held by ETFs: 
Quotes delayed 20 minutes

Hold (2.41 out of 4)
11st percentile
(ranked lower than approx. 89% of all stocks covered)

Analysts' Target Price:
IONS Stock Forecast

Based on Zacks ABR data;
powered by Xignite

Ionis Pharmaceuticals Inc (IONS) Page | The Online Investor Page |

Copyright © 1998 - 2020, All Rights Reserved
Nothing in The Online Investor is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and stock market videos powered by Market News Video. Quote data delayed at least 20 minutes; data powered by Ticker Technologies, and Mergent. Contact The Online Investor; Meet Our Editorial Staff.